BIOMAT Database Logo BIOMAT Database Logo

[Levels of circulating tumor-associated glycoprotein (TAG-72) in patients with carcinoma using a novel tumor marker, CA 72-4]. 1988

N Ohuchi, and N Matoba, and Y Taira, and K Takahashi, and N Sakai, and K Sato, and N Fujita, and F Mochizuki, and T Nishihira, and S Mori
Dept. of Surgery, Sendai City Hospital, Japan.

CA72-4 is a novel quantitative immunoradiometric assay system utilizing two monoclonal antibodies CC-49 and B72.3, which recognize a tumor-associated glycoprotein (TAG-72). We have utilized the CA72-4 RIA kit to measure serum levels of TAG-72 in 205 patients with carcinoma and 192 patients without carcinoma. The cut-off value (4.0 U/ml) was obtained according to the levels and the distribution of CA72-4 in 468 healthy individuals. The positive rates in 82 patients with gastric cancer, 55 with colorectal cancer, 24 with pancreatico-choledochal cancer, 36 with breast cancer, and 3 with ovarian cancer were 52%, 55%, 46%, 39%, and 67%, respectively. Fifty percent of the sera from 205 patients with carcinoma demonstrated increased levels of CA72-4, whereas only 10% of the sera from 192 patients without evidence of malignancy showed levels more than 4.0 U/ml. The average level of serum CA72-4 in the patients with carcinoma was 38.6 U/ml, much higher than that (2.7 U/ml) in patients without malignancy. The patients with gastrointestinal cancer at advanced stages or at recurrence showed higher levels of serum CA72-4 than the patients with cancer at early stages. These results thus indicate that CA72-4 is clinically useful as a novel tumor marker, especially for monitoring serum levels of TAG-72 in patients with gastrointestinal cancer, breast cancer, ovarian cancer and other epithelial malignancies.

UI MeSH Term Description Entries
D008297 Male Males
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D005260 Female Females
D005770 Gastrointestinal Neoplasms Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL. Gastrointestinal Cancer,Cancer of Gastrointestinal Tract,Cancer of the Gastrointestinal Tract,Neoplasms, Gastrointestinal,Cancer, Gastrointestinal,Cancers, Gastrointestinal,Gastrointestinal Cancers,Gastrointestinal Neoplasm,Gastrointestinal Tract Cancer,Gastrointestinal Tract Cancers,Neoplasm, Gastrointestinal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

N Ohuchi, and N Matoba, and Y Taira, and K Takahashi, and N Sakai, and K Sato, and N Fujita, and F Mochizuki, and T Nishihira, and S Mori
CA 72-4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma.
March 1992, Cancer research,
N Ohuchi, and N Matoba, and Y Taira, and K Takahashi, and N Sakai, and K Sato, and N Fujita, and F Mochizuki, and T Nishihira, and S Mori
[Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker].
April 1995, Geburtshilfe und Frauenheilkunde,
N Ohuchi, and N Matoba, and Y Taira, and K Takahashi, and N Sakai, and K Sato, and N Fujita, and F Mochizuki, and T Nishihira, and S Mori
Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant disease.
January 1992, Bulletin du cancer,
N Ohuchi, and N Matoba, and Y Taira, and K Takahashi, and N Sakai, and K Sato, and N Fujita, and F Mochizuki, and T Nishihira, and S Mori
Serum levels of tumor-associated glycoprotein (TAG-72) in digestive cancers.
January 1990, Oncology,
N Ohuchi, and N Matoba, and Y Taira, and K Takahashi, and N Sakai, and K Sato, and N Fujita, and F Mochizuki, and T Nishihira, and S Mori
Tumor associated glycoprotein-72 is a novel marker for poor survival in hepatocellular carcinoma.
October 2012, Pathology oncology research : POR,
N Ohuchi, and N Matoba, and Y Taira, and K Takahashi, and N Sakai, and K Sato, and N Fujita, and F Mochizuki, and T Nishihira, and S Mori
[Determination of the tumor marker CA 72-4 in gastric carcinoma].
February 1993, Revista espanola de enfermedades digestivas,
N Ohuchi, and N Matoba, and Y Taira, and K Takahashi, and N Sakai, and K Sato, and N Fujita, and F Mochizuki, and T Nishihira, and S Mori
Tumor-associated glycoprotein (TAG-72) in endometriotic implants.
April 1993, The Journal of clinical endocrinology and metabolism,
N Ohuchi, and N Matoba, and Y Taira, and K Takahashi, and N Sakai, and K Sato, and N Fujita, and F Mochizuki, and T Nishihira, and S Mori
Tumor associated glycoprotein (TAG 72) in gastric cancer.
January 1990, The Journal of nuclear medicine and allied sciences,
N Ohuchi, and N Matoba, and Y Taira, and K Takahashi, and N Sakai, and K Sato, and N Fujita, and F Mochizuki, and T Nishihira, and S Mori
CA 72-4 radioimmunoassay for the detection of the TAG-72 carcinoma-associated antigen in serum of patients.
January 1989, Journal of clinical laboratory analysis,
N Ohuchi, and N Matoba, and Y Taira, and K Takahashi, and N Sakai, and K Sato, and N Fujita, and F Mochizuki, and T Nishihira, and S Mori
Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignancies.
July 1990, British journal of cancer,
Copied contents to your clipboard!